| 381 |
New Paradigms of Care for ST-Elevation Myocardial Infarction (STEMI): Focusing on Mortality and Attributable Death Analysis in Cath-Based Care: What Do Device and Drug Trials Teach Us? |
Gregg W. Stone |
Jun. 29. 09 |
| 380 |
Achieving Optimal Clinical Results After Carotid Stenting: The PROTECT Study and Beyond... |
William A. Gray |
Jun. 23. 09 |
| 379 |
The Impact of Hemorrhagic Complications on PCI Outcomes: Lessons from ACUITY, HORIZONS and Other Trials |
Roxana Mehran |
Jun. 23. 09 |
| 378 |
How New Intravascular Imaging Techniques (VH-IVUS, OCT, IR Spectroscopy, and Others) will Change Clinical Practice in the Future |
Gary S. Mintz |
Jun. 23. 09 |
| 377 |
Is Transcatheter AVR the Standard of Care for High Risk AS Patients? Summary of Worldwide Experiences |
Martin Bert Leon |
Jun. 23. 09 |
| 376 |
Revived Indications for Thrombus Aspiration During Primary PCI: Unanswered Questions after TAPAS |
Gregg W. Stone |
Jun. 23. 09 |
| 375 |
TRITON - TIMI 38: The Future Role of Prasugrel (and Other New Anti-Platelet Agents) in PCI |
Roxana Mehran |
Jun. 23. 09 |
| 374 |
FAME: Physiologic Lesion Assessment is Necessary in Multi-Vessel PCI |
Pim A.L. Tonino |
Jun. 23. 09 |
| 373 |
SYNTAX: Anatomic Complexity Determines PCI Outcomes (Practical Use of the SYNTAX Score) |
Patrick W. Serruys |
Jun. 23. 09 |
| 372 |
HORIZONS AMI: Implications for Pharmaco-Adjunctive Therapy and DES Use |
Gregg W. Stone |
Jun. 23. 09 |
